Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1982 Aug;70(2):351–360. doi: 10.1172/JCI110624

Synthesis, Retention, and Biological Activity of Methotrexate Polyglutamates in Cultured Human Breast Cancer Cells

Jacques Jolivet 1, Richard L Schilsky 1, Brenda D Bailey 1, James C Drake 1, Bruce A Chabner 1
PMCID: PMC371243  PMID: 6178756

Abstract

To determine the pharmacologic importance of methotrexate (MTX) polyglutamates, we examined the formation, retention, and effect of these metabolites in cultured human breast cancer cells. Two cell lines (MCF-7 and ZR-75-B) converted the drug to γ-polyglutamate derivatives in a dose- and time-dependent reaction. After 24-h incubations with 2 μM MTX, polyglutamates of two to five amino acids in length accounted for 55.4% (51.9 nmol/g) of intracellular drug in the MCF-7 cells and 87.6% (62.4 nmol/g) of drug in ZR-75-B cells. In contrast, MDA-231 cells showed lesser accumulation of MTX, and only 32% (4.06 nmol/g) of the intracellular drug was in the form of polyglutamates, a difference that could only partially be explained by decreased ability of these cells to take up free drug from the medium. When MCF-7 and ZR-75-B cells containing polyglutamates were transferred to drug-free medium for 24 h, 22 and 51% of the total intracellular drug were, respectively, retained in each cell line. The loss of intracellular drug was primarily accounted for by disappearance of parent compound and polyglutamates containing 1-3 additional glutamyl residues. The rates of disappearance from cells decreased with increasing glutamyl chain length. All of the 4-NH2-10-CH3-PteGlu5 and 47 and 38% of the 4-NH2-10-CH3-PteGlu4 remained in the MCF-7 and ZR-75-B cells, respectively, and could be identified in the cytosol after 24 h in drug-free medium. The retention of MTX polyglutamates in these two cell lines in excess of dihydrofolate reductase binding capacity led to prolonged inhibition of thymidylate synthesis and loss of cell viability after removal of extracellular MTX. After 24-h incubation with 2 μM MTX and an additional 24 h in drug-free medium, [3H]deoxyuridine incorporation was still inhibited to 30% of control in the MCF-7 cells and 34.7% of control in ZR-75-B cells; this persistent inhibition was associated with a 30% reduction in cell numbers in each cell line during the 24-h period in drug-free medium. In contrast, [3H]deoxyuridine incorporation and cell growth quickly recovered to normal in the MDA-231 cells following removal of 2 μM MTX from the medium after a 24-h incubation. Prolonged inhibition of both thymidylate synthesis and cell growth was observed in this cell line in drug-free medium only after a 24-h incubation with 10 μM MTX, a condition that leads to the synthesis of 11.3 nmol/g of MTX polyglutamates.

These studies demonstrate that polyglutamate formation allows a prolonged retention of drug in a noneffluxable form and prolonged inhibition of both thymidylate synthesis and cell growth following removal of extracellular drug.

Full text

PDF
351

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balińska M., Galivan J., Coward J. K. Efflux of methotrexate and its polyglutamate derivatives from hepatic cells in vitro. Cancer Res. 1981 Jul;41(7):2751–2756. [PubMed] [Google Scholar]
  2. Baugh C. M., Krumdieck C. L., Nair M. G. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun. 1973 May 1;52(1):27–34. doi: 10.1016/0006-291x(73)90949-2. [DOI] [PubMed] [Google Scholar]
  3. Bertino J. R., Sawicki W. L., Cashmore A. R., Cadman E. C., Skeel R. T. Natural resistance to methotrexate in human acute nonlymphocytic leukemia. Cancer Treat Rep. 1977 Jul;61(4):667–673. [PubMed] [Google Scholar]
  4. Cailleau R., Young R., Olivé M., Reeves W. J., Jr Breast tumor cell lines from pleural effusions. J Natl Cancer Inst. 1974 Sep;53(3):661–674. doi: 10.1093/jnci/53.3.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Covey J. M. Polyglutamate derivatives of folic acid coenzymes and methotrexate. Life Sci. 1980 Mar 3;26(9):665–678. doi: 10.1016/0024-3205(80)90256-8. [DOI] [PubMed] [Google Scholar]
  6. Engel L. W., Young N. A., Tralka T. S., Lippman M. E., O'Brien S. J., Joyce M. J. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res. 1978 Oct;38(10):3352–3364. [PubMed] [Google Scholar]
  7. Fry D. W., Yalowich J. C., Goldman I. D. Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem. 1982 Feb 25;257(4):1890–1896. [PubMed] [Google Scholar]
  8. Galivan J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol. 1980 Jan;17(1):105–110. [PubMed] [Google Scholar]
  9. Gewirtz D. A., White J. C., Randolph J. K., Goldman I. D. Transport, binding, and polyglutamation of methotrexate in freshly isolated rat hepatocytes. Cancer Res. 1980 Mar;40(3):573–578. [PubMed] [Google Scholar]
  10. Goldman I. D., Lichtenstein N. S., Oliverio V. T. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem. 1968 Oct 10;243(19):5007–5017. [PubMed] [Google Scholar]
  11. Jacobs S. A., Derr C. J., Johns D. G. Accumulation of methotrexate diglutamate in human liver during methotrexate therapy. Biochem Pharmacol. 1977 Dec 1;26(23):2310–2313. doi: 10.1016/0006-2952(77)90296-9. [DOI] [PubMed] [Google Scholar]
  12. Jolivet J., Schilsky R. L. High-pressure liquid chromatography analysis of methotrexate polyglutamates in cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 1;30(11):1387–1390. doi: 10.1016/0006-2952(81)90330-0. [DOI] [PubMed] [Google Scholar]
  13. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  14. Myers C. E., Lippman M. E., Elliot H. M., Chabner B. A. Competitive protein binding assay for methotrexate. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3683–3686. doi: 10.1073/pnas.72.9.3683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nair M. G., Baugh C. M. Synthesis and biological evaluation of poly-gamma-glutamyl derivatives of methotrexate. Biochemistry. 1973 Sep 25;12(20):3923–3927. doi: 10.1021/bi00744a021. [DOI] [PubMed] [Google Scholar]
  16. OSBORN M. J., HUENNEKENS F. M. Enzymatic reduction of dihydrofolic acid. J Biol Chem. 1958 Oct;233(4):969–974. [PubMed] [Google Scholar]
  17. Poser R. G., Sirotnak F. M., Chello P. L. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Cancer Res. 1981 Nov;41(11 Pt 1):4441–4446. [PubMed] [Google Scholar]
  18. Poser R. G., Sirotnak F., Chello P. L. Extracellular recovery of methotrexate-polyglutamates following efflux from L1210 leukemia cells. Biochem Pharmacol. 1980 Oct 1;29(19):2701–2704. doi: 10.1016/0006-2952(80)90093-3. [DOI] [PubMed] [Google Scholar]
  19. Rosenblatt D. S., Whitehead V. M., Dupont M. M., Vuchich M. J., Vera N. Synthesis of methotrexate polyglutamates in cultured human cells. Mol Pharmacol. 1978 Jan;14(1):210–214. [PubMed] [Google Scholar]
  20. Rosenblatt D. S., Whitehead V. M., Vera N., Pottier A., Dupont M., Vuchich M. J. Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells. Mol Pharmacol. 1978 Nov;14(6):1143–1147. [PubMed] [Google Scholar]
  21. Rosowsky A., Lazarus H., Yuan G. C., Beltz W. R., Mangini L., Abelson H. T., Modest E. J., Frei E., 3rd Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts. Biochem Pharmacol. 1980 Feb 15;29(4):648–652. doi: 10.1016/0006-2952(80)90391-3. [DOI] [PubMed] [Google Scholar]
  22. Schilsky R. L., Bailey B. D., Chabner B. A. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 15;30(12):1537–1542. doi: 10.1016/0006-2952(81)90378-6. [DOI] [PubMed] [Google Scholar]
  23. Schilsky R. L., Bailey B. D., Chabner B. A. Methotrexate polyglutamate synthesis by cultured human breast cancer cells. Proc Natl Acad Sci U S A. 1980 May;77(5):2919–2922. doi: 10.1073/pnas.77.5.2919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Soule H. D., Vazguez J., Long A., Albert S., Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973 Nov;51(5):1409–1416. doi: 10.1093/jnci/51.5.1409. [DOI] [PubMed] [Google Scholar]
  25. White J. C., Loftfield S., Goldman I. D. The mechanism of action of methotrexate. III. Requirement of free intracellular methotrexate for maximal suppression of (14C)formate incorporation into nucleic acids and protein. Mol Pharmacol. 1975 May;11(3):287–297. [PubMed] [Google Scholar]
  26. Whitehead V. M., Perrault M. M., Stelcner S. Tissue-specific synthesis of methotrexate polyglutamates in the rat. Cancer Res. 1975 Nov;35(11 Pt 1):2985–2990. [PubMed] [Google Scholar]
  27. Whitehead V. M. Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells. Cancer Res. 1977 Feb;37(2):408–412. [PubMed] [Google Scholar]
  28. Witte A., Whitehead V. M., Rosenblatt D. S., Vuchich M. J. Synthesis of methotrexate polyglutamates by bone marrow cells from patients with leukemia and lymphoma. Dev Pharmacol Ther. 1980;1(1):40–46. [PubMed] [Google Scholar]
  29. Wohlhueter R. M., Marz R., Graff J. C., Plagemann P. G. The application of rapid kinetic techniques to the transport of thymidine and 3-O-Methylglucose into Mammalian cells in suspension culture. J Cell Physiol. 1976 Dec;89(4):605–612. doi: 10.1002/jcp.1040890417. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES